Monitoring low-dose warfarin therapy by a central laboratory and implications for clinical trials and patient care

In conclusion, the central laboratory provides INR results in close agreement with the local laboratory for monitoring the anticoagulant effect of low-dose warfarin. The findings suggest further evaluation of the central laboratory to monitor adjusted warfarin therapy at currently recommended therapeutic ranges.13 The cost-effectiveness of using a central laboratory should also be evaluated.